Close monitoring of cardiac performance and recognition of risk factors may minimize trastuzumab-induced cardiotoxicity in women with breast cancer.
Cardiac performance should be closely monitored in women treated with trastuzumab. Recognizing potential risk factors along with careful attention to symptoms/LVEF measurements could minimize the occurrence of TIC in this population.
Jawa et al. (Tue,) studied this question.